Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients
South San Francisco, Calif. and Cambridge, England (ots/PRNewswire) - - The partnership will support the progression of PY314, the first of Pionyr's Myeloid Tuning(TM) antibodies to enter the clinic - Pionyr will use Abcam's EPR20243 clone to evaluate TREM2 levels in tissue samples for potential future development ...